Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 280 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part 2, Placebo Group Clear all
Terminated Phase 1 Interventional

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

NCT05549323
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-07054894, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Kissimmee, Florida • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 15, 2026, 5:50 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT06241573
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 15, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

Combining Spinal Cord Transcutaneous Stimulation and Activity-based Training in Inpatient Rehabilitation to Facilitate Upper Limb Function of Individuals with Acute to Subacute Cervical Spinal Cord Injury

NCT06773286
View directory record Official record
Conditions
Spinal Cord Injury Cervical
Interventions
Active Stimulation, Sham, Training only
Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
Itacitinib, Immune effector cell therapy, Placebo, Yescarta
Drug · Biological
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

NCT00114114
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Testosterone, Goserelin acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 75 Years · Male only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 15, 2026, 5:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo for guselkumab, Etanercept
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

NCT00626275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ADL5859, Naproxen, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 15, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

NCT05694741
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD0186, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

NCT02505542
View directory record Official record
Conditions
Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects

NCT05940883
View directory record Official record
Conditions
Healthy
Interventions
Y-2 Sublingual Tablet, Placebo
Drug
Lead sponsor
Simcere Pharmaceutical Co., Ltd
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 15, 2026, 5:50 AM EDT
Terminated Phase 4 Interventional Results available

IV Lidocaine in Pediatric AIS

NCT03893318
View directory record Official record
Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
IV lidocaine, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 15, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

NCT02531633
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 15, 2026, 5:50 AM EDT
Not yet recruiting Phase 2 Interventional

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336
View directory record Official record
Conditions
Lung Transplant
Interventions
Emapalumab, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Berkeley, California • Fresno, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Study of REGN3500 and Dupilumab in Patients With Asthma

NCT03112577
View directory record Official record
Conditions
Asthma, Allergic
Interventions
REGN3500, Dupilumab, Placebo, Fluticasone propionate
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms

NCT00703534
View directory record Official record
Conditions
GERD, Acid Reflux Disease, Heartburn, Regurgitation
Interventions
AZD3355, Placebo, Gelusil®
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
84
States / cities
Athens, Alabama • Tucson, Arizona • Little Rock, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

NCT05652205
View directory record Official record
Conditions
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Interventions
Placebo for Linaclotide, Linaclotide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 5 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
38
States / cities
Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

D-Cycloserine Enhancement of Exposure in Social Phobia

NCT00633984
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Cognitive Behavioral Group Therapy (CBGT), D-Cycloserine, Placebo
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

NCT02251067
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
VPI-2690B low dose, VPI-2690B medium dose, Placebo to match VPI-2690B, VPI-2690B high dose
Drug
Lead sponsor
Vascular Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 15, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

NCT02341638
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Placebo, Aspirin, Itraconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cypress, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 15, 2026, 5:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053
View directory record Official record
Conditions
Asthma
Interventions
GSK5784283, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
51
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 15, 2026, 5:50 AM EDT